MedPath

Pyrophosphate and Arterial Calcification in Chronic Kidney Disease

Not Applicable
Recruiting
Conditions
Chronic Kidney Diseases
Registration Number
NCT04950439
Lead Sponsor
Centre Hospitalier Universitaire de Nice
Brief Summary

Arterial calcifications start at early stages of chronic kidney disease (CKD) and are associated to cardiovascular mortality. Pyrophosphate (PPi) is an endogenous compound, which stops the mineralization process in bones and is expected to act at ectopic sites. In uremic rats, low PPi plasma levels are associated with high calcium content in the aorta and peritoneal administration of PPi blocks this process. People on maintenance dialysis or kidney transplant recipients have low plasma levels of PPi and show high scores of arterial calcification. The purpose is to determine the role of low PPi in the development of arterial calcifications in patients with CKD stage 3 or 4. To that aim, 252 patients with eGFR between 59 et 20 ml/min/1,73 m2 will be recruited and will be examined at baseline and three years later.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
242
Inclusion Criteria
  • eGFR between 59 et 20 ml/min/1,73 m2 twice at three month interval
Exclusion Criteria
  1. kidney transplantation
  2. acute inflammatory disease or active cancer

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Plasma levels of PPI3 years

To show that low plasma levels of PPi at baseline is associated with a high progression of arterial calcification at three years after adjustment for confounding variables

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHU de Nice

🇫🇷

Nice, Alpes Maritimes, France

CHU de Nice
🇫🇷Nice, Alpes Maritimes, France
Favre Guillaume, PhD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.